<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00828347</url>
  </required_header>
  <id_info>
    <org_study_id>KumaNeph2</org_study_id>
    <nct_id>NCT00828347</nct_id>
  </id_info>
  <brief_title>Maintenance Vitamin D Therapy for Secondary Hyperparathyroidism (2HPT)</brief_title>
  <official_title>A Study of Maintenance Therapy After Intravenous Maxacalcitol for Secondary Hyperparathyroidism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kumamoto University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kumamoto University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are still no established protocols for maintenance therapy with intravenous or oral
      vitamin D preparations after the iPTH target has been achieved.

      Therefore, the present study compared the efficacy of two maintenance therapy protocols,
      i.e., oral administration of alfacalcidol (an oral vitamin D preparation) at a dose of 1.0
      ug/day (higher-dose group) or at a dose of 0.25 ug/day (lower-dose group), in patients with
      secondary hyperparathyroidism who responded to initial maxacalcitol therapy, resulting in the
      control of iPTH to &lt; 150 pg/mL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic kidney disease (CKD) causes various bone mineral disorders, which have recently been
      named CKD mineral and bone disorder (CKD-MBD). CKD-MBD presents a spectrum of skeletal
      abnormalities ranging from high bone turnover state such as osteitis fibrosa, which is seen
      with SHPT, to states of low bone turnover, which includes osteomalacia and adynamic bone
      disease. This disease not only increases the risk of cardiovascular disease and mortality,
      but also increases the risk of fracture. Therefore, it is important to correct the serum
      inorganic phosphorus (Pi), calcium (Ca) and parathyroid hormone (PTH) levels in dialysis
      patients, to achieve both appropriate bone turnover and to improve mortality.

      The Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines recommend that the target
      range of iPTH level for vitamin D therapy should be set at 150-300 pg/mL. In Japan, the
      mortality risk was significantly lower in the group of patients with iPTH levels &lt; 120 pg/mL
      than in the standard group set at 180 pg/mL &lt; iPTH &lt; 360 pg/mL, and lowest in the group of
      patients with 60 pg/mL &lt; iPTH &lt; 120 pg/mL . Based on these findings, Japanese guideline
      recommend that the target range of iPTH should be set at 60-180 pg/mL .

      The efficacies of various oral and intravenous vitamin D preparations for treating SHPT in
      hemodialysis patients have been reported. and oral or intravenous vitamin D pulse therapy has
      been clinically applied, especially for patients with severe SHPT.

      Up to now, the effectiveness of an oral daily alfacalcidol on SHPT has been confirmed at the
      dose of 0.25-0.5 μg /day (average 0.364μg /day), 0.5 μg /day, and 1.0 μg /day. The effective
      dose of OCT has also been verified, and furthermore, it has also been reported that
      intravenous vitamin D was more effective than oral vitamin D for suppressing PTH secretion.
      Accordingly, at present intravenous vitamin D therapy is the standard treatment for SHPT, and
      there are established protocols with regard to dosage and administration. However, no
      protocols have been established for maintenance therapy using intravenous or oral vitamin D
      preparations after the control of iPTH target range has been achieved.

      Therefore, the present study compared the efficacy of two maintenance therapy protocols for
      patients with SHPT who responded to initial OCT therapy, resulting in the control of iPTH to
      &lt;150pg/mL. One was oral administration of alfacalcidol (an oral vitamin D preparation) at a
      dose of 1.0 μg/day (higher-dose group) and the other was at a dose of 0.25 μg/day (lower-dose
      group), both of which are clinically effective doses for HD patients with SHPT.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With iPTH Levels Maintained at the Target Levels of 60-180 pg/mL iPTH Level</measure>
    <time_frame>Participants were followed for 24 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Secondary Hyperparathyroidism</condition>
  <arm_group>
    <arm_group_label>1.0 μg/day Alfacalcidol</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Alfacalcidol 1.0 μg capsule by mouth, every day for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.25 μg/day Alfacalcidol</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Alfacalcidol 0.25 μg capsule by mouth, every day for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1.0 μg/day Alfacalcidol</intervention_name>
    <description>We compared the efficacy of two protocols for maintenance therapy, which were oral administration of alfacalcidol at a dose of 1.0 μg/day in patients whose iPTH level was controlled to &lt; 150 pg/mL by initial maxacalcitol therapy.</description>
    <arm_group_label>1.0 μg/day Alfacalcidol</arm_group_label>
    <other_name>One alpha</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.25 μg/day Alfacalcidol</intervention_name>
    <description>We compared the efficacy of two protocols for maintenance therapy, which were oral administration of alfacalcidol at a dose of 0.25 μg/day in patients whose iPTH level was controlled to &lt; 150 pg/mL by initial maxacalcitol therapy.</description>
    <arm_group_label>0.25 μg/day Alfacalcidol</arm_group_label>
    <other_name>One alpha</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of secondary hyperparathyroidism (iPTH &gt;200 pg/mL to &lt;500 pg/mL)

          -  Serum Ca &lt; 11.0 mg/dL, and serum P &lt; 7.0 mg/dL.

          -  At least one year of regular hemodialysis therapy

        Exclusion Criteria:

          -  Patients with a history of hypersensitivity to any ingredient of maxacalcitol

          -  Patients who had received parathyroidectomy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masataka Adachi, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department nephrology Kumamoto University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kumamoto University Hospital</name>
      <address>
        <city>Kumamoto</city>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2009</study_first_submitted>
  <study_first_submitted_qc>January 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2009</study_first_posted>
  <results_first_submitted>July 5, 2011</results_first_submitted>
  <results_first_submitted_qc>December 16, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 25, 2016</results_first_posted>
  <last_update_submitted>December 16, 2015</last_update_submitted>
  <last_update_submitted_qc>December 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kumamoto University</investigator_affiliation>
    <investigator_full_name>Masataka Adachi</investigator_full_name>
    <investigator_title>Nephrology KU</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alfacalcidol</mesh_term>
    <mesh_term>Hydroxycholecalciferols</mesh_term>
    <mesh_term>Maxacalcitol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>High Dose Alfacalcidol</title>
          <description>oral administration of alfacalcidol at a dose of 1.0 ug/day in patients whose iPTH level was controlled to &lt; 150 pg/mL by initial maxacalcitol therapy.</description>
        </group>
        <group group_id="P2">
          <title>Low Dose Alfacalcidol</title>
          <description>oral administration of alfacalcidol at a dose of 0.25 ug/day in patients whose iPTH level was controlled to &lt; 150 pg/mL by initial maxacalcitol therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>High Dose Alfacalcidol</title>
          <description>oral administration of alfacalcidol at a dose of 1.0 ug/day in patients whose iPTH level was controlled to &lt; 150 pg/mL by initial maxacalcitol therapy.</description>
        </group>
        <group group_id="B2">
          <title>Low Dose Alfacalcidol</title>
          <description>oral administration of alfacalcidol at a dose of 0.25 ug/day in patients whose iPTH level was controlled to &lt; 150 pg/mL by initial maxacalcitol therapy.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.3" spread="9.9"/>
                    <measurement group_id="B2" value="69.0" spread="13.7"/>
                    <measurement group_id="B3" value="67.7" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With iPTH Levels Maintained at the Target Levels of 60-180 pg/mL iPTH Level</title>
        <time_frame>Participants were followed for 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Alfacalcidol</title>
            <description>oral administration of alfacalcidol at a dose of 1.0 ug/day in patients whose iPTH level was controlled to &lt; 150 pg/mL by initial maxacalcitol therapy.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Alfacalcidol</title>
            <description>oral administration of alfacalcidol at a dose of 0.25 ug/day in patients whose iPTH level was controlled to &lt; 150 pg/mL by initial maxacalcitol therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With iPTH Levels Maintained at the Target Levels of 60-180 pg/mL iPTH Level</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Controlled cases</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uncontrolled cases</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.036</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>High Dose Alfacalcidol</title>
          <description>oral administration of alfacalcidol at a dose of 1.0 ug/day in patients whose iPTH level was controlled to &lt; 150 pg/mL by initial maxacalcitol therapy.</description>
        </group>
        <group group_id="E2">
          <title>Low Dose Alfacalcidol</title>
          <description>oral administration of alfacalcidol at a dose of 0.25 ug/day in patients whose iPTH level was controlled to &lt; 150 pg/mL by initial maxacalcitol therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Sample size was small, so it will be necessary to conduct further studies in a larger number of patients.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>A study of maintenance therapy after intravenous maxacalcitol for secondary hyperparathyroidism</name_or_title>
      <organization>Department of Nephrology, Kumamoto University Graduate School of Medical Sciences</organization>
      <phone>+81-96-373-5164</phone>
      <email>m-adachi@gpo.kumamoto-u.ac.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

